

RECEIVED


JUN 3 0 2003

Michael Konkel, et al.
Serial No.: 09/764,710
Filed: January 17, 2001
Page 2


TECH CENTER 1600/2900

--2. (Twice Amended) The method of claim 7, wherein the compound binds to the human α_{1d} adrenergic receptor with a binding affinity which is at least 25-fold higher than the binding affinity with which the compound binds to (i) a human α_{1a} adrenergic receptor and (ii) a human α_{1b} adrenergic receptor, and the compound binds to the human α_{1d} adrenergic receptor with a binding affinity which is at least ten-fold higher than the binding affinity with which the compound binds to a human 5-HT_{1a} receptor.--


--8. (Amended) The method of claim 7, wherein the compound has the structure:




--9. (Amended) The method of claim 8, wherein the compound has the structure:




--10. (Amended) The method of claim 9, wherein the compound has the structure:




--17. (Amended) A compound of claim 16, wherein the compound has the structure:



--18. (Amended) A compound of claim 17, wherein the compound has the structure:




--19. (Amended) A compound of claim 18, wherein the compound has the structure:




--38. (Amended) A method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a α_{1d} adrenergic

receptor antagonist, which binds to the human α_{1d} adrenergic receptor with a binding affinity which is at least 10-fold higher than the binding affinity with which the compound binds to (i) a human α_{1a} adrenergic receptor and (ii) a human α_{1b} adrenergic receptor, and the compound binds to the human α_{1d} adrenergic receptor with a binding affinity which is at least ten-fold higher than the binding affinity with which the compound binds to a human 5-HT_{1a} receptor, wherein the α_{1d} adrenergic receptor antagonist has the structure:



wherein each m and n is independently an integer from 0 to 2;

wherein each Y and Z is independently



wherein R1 and R2 (i) are independently H, branched or unbranched C₁-C₆ alkyl or alkoxy, branched or unbranched C₂-C₆ alkenyl or alkynyl, branched or unbranched C₁-C₆ hydroxyalkyl, hydroxy, substituted or unsubstituted aryl or aryl-(C₁-C₆)-alkyl, or substituted or unsubstituted heteroaryl or heteroaryl-(C₁-C₆)-alkyl, wherein the substituent if present is a halogen, CN, nitro, hydroxy, branched or unbranched C₁-C₆ alkyl or alkoxy group, or branched or unbranched C₂-C₆ alkenyl or alkynyl group; or

(ii) taken together form a substituted or unsubstituted cycloalkyl ring containing 3-10 carbons, wherein the substituent if present is a branched or unbranched C₁-C₆ alkyl group or branched or unbranched C₂-C₆ alkenyl or alkynyl group;

wherein R₃ is H, branched or unbranched C₁-C₆ alkyl, branched or unbranched C₂-C₆ alkenyl or alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkylalkyl, aryl, heteroaryl, aryl-(C₁-C₆)-alkyl, heteroaryl-(C₁-C₆)-alkyl, substituted C₁-C₆ alkyl, substituted C₃-C₇ cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C₁-C₆)-alkyl, or substituted heteroaryl-(C₁-C₆)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C₁-C₆ alkyl, OR₁₄, SR₁₄, N(R₁₄)₂, SO₂N(R₁₄)₂, CO₂R₁₄, SO₃R₁₄, N(R₁₄)COR₁₄, CON(R₁₄)₂, or N(R₁₄)CON(R₁₄)₂;

wherein R₄ is H or CH₃;

wherein R₅ is H, branched or unbranched C₁-C₆ alkyl, branched or unbranched C₂-C₆ alkenyl or alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkylalkyl, aryl, heteroaryl, aryl-(C₁-C₆)-alkyl, heteroaryl-(C₁-C₆)-alkyl, substituted C₁-C₆ alkyl, substituted C₃-C₇ cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C₁-C₆)-alkyl, or substituted heteroaryl-(C₁-C₆)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C₁-C₆ alkyl, OR₁₄, SR₁₄, N(R₁₄)₂, SO₂N(R₁₄)₂, CO₂R₁₄, SO₃R₁₄, N(R₁₄)COR₁₄, CON(R₁₄)₂, or N(R₁₄)CON(R₁₄)₂;

wherein R₆ is H, branched or unbranched C₁-C₆ alkyl, branched or unbranched C₂-C₆ alkenyl or alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkylalkyl, aryl, heteroaryl, aryl-

(C₁-C₆)-alkyl, heteroaryl-(C₁-C₆)-alkyl, substituted C₁-C₆ alkyl, substituted C₃-C₇ cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C₁-C₆)-alkyl, or substituted heteroaryl-(C₁-C₆)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C₁-C₆ alkyl, OR₁₄, SR₁₄, N(R₁₄)₂, SO₂N(R₁₄)₂, CO₂R₁₄, SO₃R₁₄, N(R₁₄)COR₁₄, CON(R₁₄)₂, or N(R₁₄)CON(R₁₄)₂;

wherein R₇ is H, branched or unbranched C₁-C₆ alkyl, branched or unbranched C₂-C₆ alkenyl or alkynyl, C₃-C₇ cycloalkyl, aryl, aryl-(C₁-C₆)-alkyl, CO₂R₁₄, CON(R₁₄)₂, substituted C₁-C₆ alkyl, substituted aryl, wherein the substituent is N(R₁₄)₂, halogen, OR₁₄ or SR₁₄;

wherein R₈ is H or CH₃;

wherein R₁₀ is H or F; wherein R₁₁ is H, F, Cl, Br, I, CN, branched or unbranched C₁-C₆ alkyl or alkoxy; wherein R₁₃ is H or F;

and wherein R₁₄ is independently H or branched or unbranched C₁-C₆ alkyl.--

Please add new claims 43 and 44 as follows:

--43. (New) The compound of claim 16, wherein the compound comprises the (-) enantiomer.--

--44. (New) The compound of claim 16, wherein the compound comprises the (+) enantiomer.-